375 related articles for article (PubMed ID: 26545048)
21. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
Sahm F; Reuss D; Koelsche C; Capper D; Schittenhelm J; Heim S; Jones DT; Pfister SM; Herold-Mende C; Wick W; Mueller W; Hartmann C; Paulus W; von Deimling A
Acta Neuropathol; 2014 Oct; 128(4):551-9. PubMed ID: 25143301
[TBL] [Abstract][Full Text] [Related]
22. Mutations in CIC and FUBP1 contribute to human oligodendroglioma.
Bettegowda C; Agrawal N; Jiao Y; Sausen M; Wood LD; Hruban RH; Rodriguez FJ; Cahill DP; McLendon R; Riggins G; Velculescu VE; Oba-Shinjo SM; Marie SK; Vogelstein B; Bigner D; Yan H; Papadopoulos N; Kinzler KW
Science; 2011 Sep; 333(6048):1453-5. PubMed ID: 21817013
[TBL] [Abstract][Full Text] [Related]
23. Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report.
Takami H; Mukasa A; Takayanagi S; Koike T; Matsuura R; Ikemura M; Ushiku T; Yoshikawa G; Shibahara J; Tanaka S; Saito N
Brain Tumor Pathol; 2023 Jan; 40(1):26-34. PubMed ID: 36572828
[TBL] [Abstract][Full Text] [Related]
24. IDH-Mutant Astrocytoma With Chromosome 19q13 Deletion Manifesting as an Oligodendroglioma-Like Morphology.
Miyake Y; Fujii K; Nakamaura T; Ikegaya N; Matsushita Y; Gobayashi Y; Iwashita H; Udaka N; Kumagai J; Murata H; Takemoto Y; Yamanaka S; Ichimura K; Tateishi K; Yamamoto T
J Neuropathol Exp Neurol; 2021 Feb; 80(3):247-253. PubMed ID: 33432322
[TBL] [Abstract][Full Text] [Related]
25. Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report.
Ono T; Reinhardt A; Takahashi M; Nanjo H; Kamataki A; von Deimling A; Shimizu H
Acta Neurochir (Wien); 2020 Dec; 162(12):3019-3024. PubMed ID: 32785787
[TBL] [Abstract][Full Text] [Related]
26. Network-based analysis of oligodendrogliomas predicts novel cancer gene candidates within the region of the 1p/19q co-deletion.
Gladitz J; Klink B; Seifert M
Acta Neuropathol Commun; 2018 Jun; 6(1):49. PubMed ID: 29890994
[TBL] [Abstract][Full Text] [Related]
27. Alpha-internexin and altered CIC expression as a supportive diagnostic marker for oligodendroglial tumors with the 1p/19q co-deletion.
Nagaishi M; Suzuki A; Nobusawa S; Yokoo H; Nakazato Y
Brain Tumor Pathol; 2014 Oct; 31(4):257-64. PubMed ID: 24197863
[TBL] [Abstract][Full Text] [Related]
28. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
Andrews C; Prayson RA
Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
[TBL] [Abstract][Full Text] [Related]
29. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
[TBL] [Abstract][Full Text] [Related]
30. Rare occurrence of IDH2 mutation in adolescent oligodendroglioma with 1p/19q co-deletion: a case report.
Rao S; Sivakoti S; Arivazhagan A; Santosh V
Childs Nerv Syst; 2020 Dec; 36(12):3109-3113. PubMed ID: 32296936
[TBL] [Abstract][Full Text] [Related]
31. [Diagnostic and prognostic roles of loss of CIC protein expression in oligodendroglial tumors].
Liu CC; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH; Piao YS
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):679-683. PubMed ID: 29050068
[No Abstract] [Full Text] [Related]
32. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
Jiang H; Ren X; Cui X; Wang J; Jia W; Zhou Z; Lin S
Neuro Oncol; 2013 Jun; 15(6):775-82. PubMed ID: 23486687
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic, prognostic and predictive relevance of molecular markers in gliomas.
Brandner S; von Deimling A
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):694-720. PubMed ID: 25944653
[TBL] [Abstract][Full Text] [Related]
34. [IDH、TERT and 1p/19q predicting clinical outcomes in patients with anaplastic oligodendroglioma].
Ji YC; Zhan YB; Liu XZ; Zhang ZY
Zhonghua Yi Xue Za Zhi; 2019 Jul; 99(25):1959-1962. PubMed ID: 31269600
[No Abstract] [Full Text] [Related]
35. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
36. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression.
Reyes-Botero G; Dehais C; Idbaih A; Martin-Duverneuil N; Lahutte M; Carpentier C; Letouzé E; Chinot O; Loiseau H; Honnorat J; Ramirez C; Moyal E; Figarella-Branger D; Ducray F;
Neuro Oncol; 2014 May; 16(5):662-70. PubMed ID: 24353325
[TBL] [Abstract][Full Text] [Related]
37. Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors.
Chen H; Thomas C; Munoz FA; Alexandrescu S; Horbinski CM; Olar A; McGuone D; Camelo-Piragua S; Wang L; Pentsova E; Phillips J; Aldape K; Chen W; Iafrate AJ; Chi AS; Zagzag D; Golfinos JG; Placantonakis DG; Rosenblum M; Ohman-Strickland P; Hameed M; Snuderl M
Neuro Oncol; 2019 Sep; 21(9):1164-1174. PubMed ID: 31140557
[TBL] [Abstract][Full Text] [Related]
38. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas.
Burford C; Laxton R; Sidhu Z; Aizpurua M; King A; Bodi I; Ashkan K; Al-Sarraj S
Br J Neurosurg; 2019 Oct; 33(5):536-540. PubMed ID: 31018710
[No Abstract] [Full Text] [Related]
39. Clinical implications of molecular analysis in diffuse glioma stratification.
Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
[TBL] [Abstract][Full Text] [Related]
40. HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
Felix M; Friedel D; Jayavelu AK; Filipski K; Reinhardt A; Warnken U; Stichel D; Schrimpf D; Korshunov A; Wang Y; Kessler T; Etminan N; Unterberg A; Herold-Mende C; Heikaus L; Sahm F; Wick W; Harter PN; von Deimling A; Reuss DE
Neuro Oncol; 2022 Dec; 24(12):2121-2132. PubMed ID: 35511748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
